India Is World's Largest Vaccine Producer by Volume: Minister

The correct answer is Coalition for Epidemic Preparedness Innovations. Its Board and Investors Council met in New Delhi, and the Department of Biotechnology and CEPI jointly hosted a high-level evening reception at the India International Centre. The meeting brought the organisation's governance back to India after a decade. India is a founding member of the coalition and a long-standing strategic partner. The Department of Biotechnology and BIRAC work with CEPI under a tripartite engagement strategy that was first executed in October 2019 and renewed in September 2025 for another five years. Options A, C and D are invented expansions and none of them appears in the release. Abbreviations of international health bodies are asked very often, so learn the exact words behind each letter rather than a rough sense of what the body does.

The correct answer is USD 195.3 billion. India's bioeconomy reached that size in 2025 and recorded eighteen per cent growth over the previous year. The country's biotech startup ecosystem expanded to 11,855 startups, of which 1,780 were added in that single year, and the biopharma sector accounts for nearly thirty per cent of the bioeconomy. The Minister used these figures to argue that India's capabilities can no longer be seen only through the prism of vaccine manufacturing, since the country has moved into advanced vaccine technologies and complex biological products. Options A, B and D give sizes that do not appear in the release. In examinations a figure like this is usually paired with its year and its growth rate, so remember the three together rather than the amount alone.

The correct answer is GEMCOVAC-19. The India-centric CEPI mission, Ind-CEPI, is implemented by BRIC-THSTI and BIRAC, and this vaccine was among its important outcomes. It received Emergency Use Authorisation. Other results of the mission include an inactivated chikungunya vaccine candidate now in Phase II and Phase III trials, and candidates against monkeypox and pan-sarbecoviruses built on Multivalent Self-assembled Nanocage technology, which are at an advanced pre-clinical stage. The partnership also created shared infrastructure: the BRIC-THSTI Bioassay Laboratory is one of CEPI's 17 centralised network laboratories and has supported eight vaccine candidates. Options B, C and D are invented names that do not appear in the release. Candidates should keep the vaccine name, the platform used and the mission that produced it together in memory.